Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

41.04 +0.23 (+0.56%)
Official Closing Price Updated: 7:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,639,733
Open 40.55
Bid (Size) 41.05 (1)
Ask (Size) 41.11 (5)
Prev. Close 40.81
Today's Range 39.63 - 41.19
52wk Range 39.63 - 66.38
Shares Outstanding 2,222,113,553
Dividend Yield 5.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
-22.21%
-22.21%
1 Month
-2.91%
-2.91%
3 Month
-20.45%
-20.45%
6 Month
-19.94%
-19.94%
1 Year
-37.34%
-37.34%

More News

Read More
3 Warren Buffett Stocks to Buy Now: June 2024
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over?
Via Talk Markets
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
From Bristol Myers Squibb
Via Business Wire
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Via The Motley Fool
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Smart Money Is Betting Big In BMY Options
Via Benzinga
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
Via FinancialNewsMedia
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 High-Yield Dividend Stocks for Income Now and Growth Later
Via MarketBeat
Topics Economy
Exposures Interest Rates
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
Via InvestorPlace
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
Via InvestorPlace
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Via Benzinga
Exposures Product Safety
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Via Benzinga
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Via Benzinga
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.